secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0000950170-22-018315
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND
--------------------------------------------------------------------------------

- First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.
- Initiated Phase 1/2 ACHIEVE trial for DYNE-101 in DM1; first patient expected in September 2022; target ~64 adult patients.
- Deferring IND submission for DYNE-301 (FSHD) originally planned for H2 2022; update expected in 2023.
- Cash runway extended through 2024 due to FSHD program deferral, based on existing cash and equivalents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/0000950170-22-018315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/dyn-20220906.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer